Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vilin Bio MedNSE:VILINBIO +4.93%69 Gross Margin % is 12.08% as of Mar. 2026, which is 32% below its 10-year median of 17.71. GuruFocus rates NSE:VILINBIO with a GF Score™ of 69/100 and a GF Value™ of ₹75.10 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 939 Drug Manufacturers companies, Vilin Bio Med ranks worse than 94.78% on this metric.
Vilin Bio Med Ltd gross margin has been in long-term decline. The average rate of decline per year is -16.3%.
The historical rank and industry rank for Vilin Bio Med's Gross Margin % or its related term are showing as below:
NSE:VILINBIO'
s Gross Margin % Range Over the Past 10 Years
Min: 9.03 Med: 17.71 Max: 41.76
Current: 12.08
During the past 7 years, the highestGross Margin % of Vilin Bio Med was 41.76%. The lowest was 9.03%. And the median was 17.71%.
NSE:VILINBIO's Gross Margin % is ranked worse than 94.78% of 939
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs NSE:VILINBIO: 12.08
Vilin Bio Med had a gross margin of 12.08% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Vilin Bio Med was -16.30% per year.
Vilin Bio Med (NSE:VILINBIO) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vilin Bio Med had a gross margin of 12.08% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vilin Bio Med Gross Margin % Related Terms
Vilin Bio Med Gross Margin % Historical Data
* Premium members only.
The historical data trend for Vilin Bio Med's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vilin Bio Med (NSE:VILINBIO) has a Gross Margin % of 12.08% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Vilin Bio Med and its competitors. This is 32% below median its historical median of 17.71. Over the past decade, Vilin Bio Med's Gross Margin % has ranged from 9.03 to 41.76. According to the industry distribution chart, Vilin Bio Med ranks #890 out of 939 companies in the Drug Manufacturers industry, placing it in the top 94.8%.
Is Vilin Bio Med's Gross Margin % too high?
Vilin Bio Med's current Gross Margin % of 12.08% is 32% below median its 10-year median of 17.71. Over the past 10 years, this metric has ranged from a low of 9.03 to a high of 41.76. The Drug Manufacturers industry median Gross Margin % is 48.54. Vilin Bio Med's value of 12.08% is 75.1% below this industry median. Based on the distribution chart, Vilin Bio Med ranks #890 out of 939 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #890 out of 939 companies for Gross Margin %. This places Vilin Bio Med in the lower half of its industry. The industry median Gross Margin % is 48.54. Vilin Bio Med's value of 12.08% is 75.1% below this benchmark. Historically, Vilin Bio Med's own Gross Margin % has ranged from 9.03 to 41.76 over the past decade. While the company's 10-year median is 17.71 vs. the industry median of 48.54, Vilin Bio Med has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vilin Bio Med's current Gross Margin % of 12.08% is 75.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current Gross Margin % is 12.08%, which is 32% below median its own 10-year median of 17.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current Gross Margin % is 12.08%, which is 32% below median its 10-year median of 17.71 and 75.1% below the Drug Manufacturers industry median of 48.54. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current Gross Margin % is 12.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
Gross Margin %: 12.08% (32% below median its 10-year median of 17.71)
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
Industry Position: 75.1% below the Drug Manufacturers median (#890 of 939)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
